Donanemab Clinical Trials
3 recruitingDrug
Phase 31Phase 21
Showing 1–3 of 3 trials
Recruiting
Phase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Cognitive DysfunctionLewy Body DiseaseAmyloid+1 more
Eli Lilly and Company350 enrolled72 locationsNCT07589595
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Alzheimer Disease
Eli Lilly and Company6,250 enrolled1 locationNCT06566170